Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy.

MLA

Sabatos-Peyton, Catherine A., et al. “Blockade of Tim-3 Binding to Phosphatidylserine and CEACAM1 Is a Shared Feature of Anti-Tim-3 Antibodies That Have Functional Efficacy.” OncoImmunology, vol. 7, no. 2, Feb. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1080/2162402X.2017.1385690.

APA

Sabatos-Peyton, C. A., Nevin, J., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J., Wesemann, L., Pertel, T., Acharya, N., Klapholz, M., Etminan, Y., Jiang, X., Huang, Y.-H., Blumberg, R. S., Kuchroo, V. K., & Anderson, A. C. (2018). Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology, 7(2), N.PAG. https://doi.org/10.1080/2162402X.2017.1385690

Chicago

Sabatos-Peyton, Catherine A., James Nevin, Ansgar Brock, John D. Venable, Dewar J. Tan, Nasim Kassam, Fangmin Xu, et al. 2018. “Blockade of Tim-3 Binding to Phosphatidylserine and CEACAM1 Is a Shared Feature of Anti-Tim-3 Antibodies That Have Functional Efficacy.” OncoImmunology 7 (2): N.PAG. doi:10.1080/2162402X.2017.1385690.